{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:48Z","timestamp":1788922188621,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale<\/jats:title>\n            <jats:p>Both topiramate and naltrexone have been shown to affect neural alcohol cue reactivity in alcohol use disorder (AUD). However, their comparative effects on alcohol cue reactivity are unknown. Moreover, while naltrexone has been found to normalize hyperactive localized network connectivity implicated in AUD, no studies have examined the effect of topiramate on intrinsic functional connectivity or compared functional connectivity between these two widely used medications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study compared topiramate versus naltrexone on alcohol cue-elicited brain activation and intrinsic functional connectivity in patients with alcohol use disorder.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Forty-seven participants with alcohol use disorder received daily topiramate (titrating the dose up to 200\u00a0mg\/day <jats:italic>n<\/jats:italic>\u2009=\u200921) or naltrexone (50\u00a0mg\/day, <jats:italic>n<\/jats:italic>\u2009=\u200926) for at least 6 weeks. Using functional magnetic resonance imaging (fMRI), we examined intrinsic functional connectivity during rest and alcohol cue-elicited neural activation during a visual alcohol cue reactivity task 120\u00a0min following treatment administration. Functional connectivity and alcohol cue reactivity and percentage of heavy drinking days (% HDD) associations were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No differences in either intrinsic functional connectivity or alcohol cue-elicited neural activity were seen between topiramate and naltrexone-treated groups. Overall, participants showed increased alcohol cue-elicited activation in three clusters spanning occipital regions involved in visual recognition of stimuli, and hypoactivation to both alcohol and control cues in three clusters involved in salience attribution and processing of emotional valence of external stimuli. No differences between topiramate versus naltrexone were observed for either functional measure or associations with post-scan % HDD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Topiramate and naltrexone enacted comparable alcohol cue reactivity and intrinsic functional connectivity patterns. Some overall responses of increased brain activation to alcohol cues in visual processing regions coupled with reduced activation to alcohol and control cues were evidenced for both treatments. These activation patterns were in regions expected to show attenuation of brain activity resulting from treatment. Topiramate and naltrexone may thus enact functional effects through similar modulation of functional neural activity in individuals with AUD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov, NCT03479086 <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT03479086\" ext-link-type=\"uri\">https:\/\/www.clinicaltrials.gov\/study\/NCT03479086<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00213-025-06745-7","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:09:10Z","timestamp":1737695350000},"page":"1641-1652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neural cue reactivity and intrinsic functional connectivity in individuals with alcohol use disorder following treatment with topiramate or naltrexone"],"prefix":"10.1007","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0777-3033","authenticated-orcid":false,"given":"Warren B.","family":"Logge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Hurzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kranzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten C.","family":"Morley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"6745_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","volume":"94","author":"M \u00c4ngehagen","year":"2005","unstructured":"\u00c4ngehagen M, R\u00f6nnb\u00e4ck L, Hansson E, Ben-Menachem E (2005) Topiramate reduces AMPA-induced Ca2\u2009+\u2009transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem 94:1124\u20131130","journal-title":"J Neurochem"},{"key":"6745_CR2","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1111\/j.1530-0277.2012.01807.x","volume":"36","author":"RF Anton","year":"2012","unstructured":"Anton RF, Voronin KK, Randall PK, Myrick H, Tiffany A (2012) Naltrexone Modification of drinking effects in a Subacute Treatment and Bar-Lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcoholism: Clin Experimental Res 36:2000\u20132007","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"6745_CR3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1176\/appi.ajp.20220821","volume":"179","author":"J Avery","year":"2022","unstructured":"Avery J (2022) Naltrexone and Alcohol Use. Am J Psychiatry 179:886\u2013887","journal-title":"Am J Psychiatry"},{"key":"6745_CR4","doi-asserted-by":"publisher","first-page":"e12717","DOI":"10.1111\/adb.12717","volume":"25","author":"P Bach","year":"2020","unstructured":"Bach P, Weil G, Pompili E et al (2020) Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. Addict Biol 25:e12717","journal-title":"Addict Biol"},{"key":"6745_CR5","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1111\/j.1360-0443.2008.02355.x","volume":"103","author":"DA Baltieri","year":"2008","unstructured":"Baltieri DA, Dar\u00f3 FR, Ribeiro PL, De Andrade AG (2008) Comparing topiramate with naltrexone in the treatment of alcohol dependence*. Addiction 103:2035\u20132044","journal-title":"Addiction"},{"key":"6745_CR6","doi-asserted-by":"publisher","unstructured":"Beck A, Pelz P, Lorenz RC et al (2018) Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. Eur Neuropsychopharmacol 28(11):1206\u20131216. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.08.507","DOI":"10.1016\/j.euroneuro.2018.08.507"},{"key":"6745_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false Discovery rate: a practical and powerful Approach to multiple testing. J Roy Stat Soc: Ser B (Methodol) 57:289\u2013300","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"6745_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.neuroimage.2012.01.090","volume":"62","author":"BB Biswal","year":"2012","unstructured":"Biswal BB (2012) Resting state fMRI: a personal history. NeuroImage 62:938\u2013944","journal-title":"NeuroImage"},{"key":"6745_CR75","doi-asserted-by":"publisher","unstructured":"Blodgett JC, Del Re AC, Maisel NC, Finney JW. (2014) A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. ACER 38:1481\u20131488. https:\/\/doi.org\/10.1111\/acer.12411","DOI":"10.1111\/acer.12411"},{"key":"6745_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1530-0277.1995.tb01554.x","volume":"19","author":"MJ Bohn","year":"1995","unstructured":"Bohn MJ, Krahn DD, Staehler BA (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcoholism: Clin Experimental Res 19:600\u2013606","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"6745_CR10","unstructured":"Brett M, Anton J-L, Valabregue R, Poline J-B (2002) Region of interest analysis using an SPM toolbox. 1"},{"key":"6745_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neuroimage.2017.03.020","volume":"154","author":"R Ciric","year":"2017","unstructured":"Ciric R, Wolf DH, Power JD et al (2017) Benchmarking of participant-level confound regression strategies for the control of motion artifact in studies of functional connectivity. NeuroImage 154:174\u2013187","journal-title":"NeuroImage"},{"key":"6745_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/adb.12314","volume":"21","author":"KE Courtney","year":"2016","unstructured":"Courtney KE, Schacht JP, Hutchison K, Roche DJO, Ray LA (2016) Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addict Biol 21:3\u201322","journal-title":"Addict Biol"},{"key":"6745_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s002130051085","volume":"146","author":"H de Wit","year":"1999","unstructured":"de Wit H, Svenson J, York A (1999) Non-specific effect of naltrexone on ethanol consumption in social drinkers. Psychopharm 146:33\u201341","journal-title":"Psychopharm"},{"key":"6745_CR14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","volume":"28","author":"DJ Drobes","year":"2004","unstructured":"Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of Naltrexone and Nalmefene on subjective response to Alcohol among Non-treatment-seeking alcoholics and Social drinkers. Alcoholism: Clin Experimental Res 28:1362\u20131370","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"6745_CR15","doi-asserted-by":"crossref","unstructured":"Eklund A, Nichols TE, Knutsson H (2016) Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. Proceedings of the National Academy of Sciences 113: 7900-05","DOI":"10.1073\/pnas.1602413113"},{"key":"6745_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/acer.13999","volume":"43","author":"A Elton","year":"2019","unstructured":"Elton A, Dove S, Spencer CN, Robinson DL, Boettiger CA (2019) Naltrexone acutely enhances Connectivity between the Ventromedial Prefrontal Cortex and a left Frontoparietal Network. Alcoholism: Clin Experimental Res 43:965\u2013978","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"6745_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41592-018-0235-4","volume":"16","author":"O Esteban","year":"2019","unstructured":"Esteban O, Markiewicz CJ, Blair RW et al (2019) fMRIPrep: a robust preprocessing pipeline for functional MRI. Nat Methods 16:111\u2013116","journal-title":"Nat Methods"},{"key":"6745_CR17","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41596-020-0327-3","volume":"15","author":"O Esteban","year":"2020","unstructured":"Esteban O, Ciric R, Finc K et al (2020) Analysis of task-based functional MRI data preprocessed with fMRIPrep. Nat Protoc 15:2186\u20132202","journal-title":"Nat Protoc"},{"key":"6745_CR19","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/j.1530-0277.2010.01290.x","volume":"34","author":"D Falk","year":"2010","unstructured":"Falk D, Wang XQ, Liu L et al (2010) Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for AlcoholClinical trials. Alcoholism: Clin Experimental Res 34:2022\u20132034","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"6745_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/j.1530-0277.2008.00680.x","volume":"32","author":"G Fl\u00f3rez","year":"2008","unstructured":"Fl\u00f3rez G, Garc\u00eda-Portilla P, \u00c1lvarez S, Saiz PA, Nogueiras L, Bobes J (2008) Using Topiramate or Naltrexone for the treatment of alcohol-dependent patients. Alcoholism: Clin Experimental Res 32:1251\u20131259","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"6745_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000320471","volume":"17","author":"G Fl\u00f3rez","year":"2010","unstructured":"Fl\u00f3rez G, Saiz PA, Garc\u00eda-Portilla P, \u00c1lvarez S, Nogueiras L, Bobes J (2010) Topiramate for the Treatment of Alcohol Dependence: comparison with Naltrexone. Eur Addict Res 17:29\u201336","journal-title":"Eur Addict Res"},{"key":"6745_CR22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/imj.13237","volume":"46","author":"CH Freyer","year":"2016","unstructured":"Freyer CH, Morley KC, Haber PS (2016) Alcohol use disorders in Australia. Intern Med J 46:1259\u20131268","journal-title":"Intern Med J"},{"key":"6745_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00213-004-1828-4","volume":"175","author":"SM Gr\u00fcsser","year":"2004","unstructured":"Gr\u00fcsser SM, Wrase J, Klein S et al (2004) Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharm 175:296\u2013302","journal-title":"Psychopharm"},{"key":"6745_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40263-015-0244-0","volume":"29","author":"R Guglielmo","year":"2015","unstructured":"Guglielmo R, Martinotti G, Quatrale M et al (2015) Topiramate in Alcohol Use disorders: Review and Update. CNS Drugs 29:383\u2013395","journal-title":"CNS Drugs"},{"key":"6745_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neuron.2008.09.012","volume":"60","author":"BY Hayden","year":"2008","unstructured":"Hayden BY, Nair AC, McCoy AN, Platt ML (2008) Posterior cingulate cortex mediates outcome-contingent allocation of Behavior. Neuron 60:19\u201325","journal-title":"Neuron"},{"key":"6745_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.9758\/cpn.2018.16.3.290","volume":"16","author":"B Holla","year":"2018","unstructured":"Holla B, Karthik S, Biswal J et al (2018) Brain functional magnetic resonance imaging cue-reactivity can predict Baclofen Response in Alcohol Use disorders. Clin Psychopharmacol Neurosci 16:290\u2013301","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"6745_CR27","doi-asserted-by":"publisher","first-page":"12385","DOI":"10.1523\/JNEUROSCI.2180-16.2016","volume":"36","author":"A Jahn","year":"2016","unstructured":"Jahn A, Nee DE, Alexander WH, Brown JW (2016) Distinct regions within medial prefrontal cortex process Pain and Cognition. J Neurosci 36:12385","journal-title":"J Neurosci"},{"key":"6745_CR28","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","volume":"361","author":"BA Johnson","year":"2003","unstructured":"Johnson BA, Ait-Daoud N, Bowden CL et al (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677\u20131685","journal-title":"Lancet"},{"key":"6745_CR29","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","volume":"298","author":"BA Johnson","year":"2007","unstructured":"Johnson BA, Rosenthal N, Capece JA et al (2007) Topiramate for Treating Alcohol DependenceA Randomized Controlled Trial. JAMA 298:1641\u20131651","journal-title":"JAMA"},{"key":"6745_CR30","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C et al (2014) Pharmacotherapy for adults with Alcohol Use disorders in Outpatient settings: a systematic review and Meta-analysis. JAMA 311:1889\u20131900","journal-title":"JAMA"},{"key":"6745_CR31","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00213-015-3882-5","volume":"232","author":"F Kiefer","year":"2015","unstructured":"Kiefer F, Kirsch M, Bach P et al (2015) Effects of d-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial. Psychopharm 232:2353\u20132362","journal-title":"Psychopharm"},{"key":"6745_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.drugalcdep.2018.07.045","volume":"192","author":"M Kohno","year":"2018","unstructured":"Kohno M, Dennis LE, McCready H, Schwartz DL, Hoffman WF, Korthuis PT (2018) A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug Alcohol Depend 192:186\u2013192","journal-title":"Drug Alcohol Depend"},{"key":"6745_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2018.11406","volume":"320","author":"HR Kranzler","year":"2018","unstructured":"Kranzler HR, Soyka M (2018) Diagnosis and pharmacotherapy of Alcohol Use Disorder: a review. JAMA 320:815\u2013824","journal-title":"JAMA"},{"key":"6745_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Covault J, Feinn R et al (2014) Topiramate Treatment for Heavy drinkers: Moderation by a GRIK1 polymorphism. Am J Psychiatry 171:445\u2013452","journal-title":"Am J Psychiatry"},{"key":"6745_CR34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41386-020-00945-9","volume":"46","author":"HR Kranzler","year":"2021","unstructured":"Kranzler HR, Morris PE, Pond T et al (2021) Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder. Neuropsychopharmacology 46:1407\u20131413","journal-title":"Neuropsychopharmacology"},{"key":"6745_CR36","first-page":"3","volume":"1","author":"PJ Lang","year":"1997","unstructured":"Lang PJ, Bradley MM, Cuthbert BN (1997) International affective picture system (IAPS): technical manual and affective ratings. NIMH Cent Study Emot Atten 1:3","journal-title":"NIMH Cent Study Emot Atten"},{"key":"6745_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/hbm.22168","volume":"35","author":"W Li","year":"2014","unstructured":"Li W, van Tol M-J, Li M et al (2014) Regional specificity of sex effects on subcortical volumes across the lifespan in healthy aging. Hum Brain Mapp 35:238\u2013247","journal-title":"Hum Brain Mapp"},{"key":"6745_CR39","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00213-019-05192-5","volume":"238","author":"WB Logge","year":"2021","unstructured":"Logge WB, Morris RW, Baillie AJ, Haber PS, Morley KC (2021) Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharm 238:1291\u20131302","journal-title":"Psychopharm"},{"key":"6745_CR38","doi-asserted-by":"crossref","unstructured":"Logge WB, Haber PS, Hurzeler TP, Towers EE, Morley KC (2024) The effects of N-acetyl cysteine on intrinsic functional connectivity and neural alcohol cue reactivity in treatment-seeking individuals with alcohol use disorder: a preliminary study. Psychopharm","DOI":"10.1101\/2023.10.18.23297059"},{"key":"6745_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.neuroimage.2013.03.055","volume":"78","author":"SE Lukas","year":"2013","unstructured":"Lukas SE, Lowen SB, Lindsey KP et al (2013) Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. NeuroImage 78:176\u2013185","journal-title":"NeuroImage"},{"key":"6745_CR41","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1111\/acer.12546","volume":"38","author":"K Mann","year":"2014","unstructured":"Mann K, Vollst\u00e4dt-Klein S, Reinhard I et al (2014) Predicting Naltrexone Response in Alcohol-Dependent patients: the contribution of functional magnetic resonance imaging. Alcoholism: Clin Experimental Res 38:2754\u20132762","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"6745_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.neuroimage.2016.02.053","volume":"132","author":"M McFarquhar","year":"2016","unstructured":"McFarquhar M, McKie S, Emsley R, Suckling J, Elliott R, Williams S (2016) Multivariate and repeated measures (MRM): a new toolbox for dependent and multimodal group-level neuroimaging data. NeuroImage 132:373\u2013389","journal-title":"NeuroImage"},{"key":"6745_CR43","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cct.2013.09.003","volume":"36","author":"J Millum","year":"2013","unstructured":"Millum J, Grady C (2013) The ethics of placebo-controlled trials: methodological justifications. Contemp Clin Trials 36:510\u2013514","journal-title":"Contemp Clin Trials"},{"key":"6745_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1530-0277.2007.00592.x","volume":"32","author":"R Miranda Jr","year":"2008","unstructured":"Miranda R Jr, MacKillop J, Monti PM et al (2008) Effects of Topiramate on urge to drink and the subjective effects of Alcohol: a preliminary Laboratory Study. Alcohol Clin Exp Res 32:489\u2013497","journal-title":"Alcohol Clin Exp Res"},{"key":"6745_CR45","first-page":"297","volume":"18","author":"S Moradi","year":"2013","unstructured":"Moradi S, Kerman SRJ, Mollabashi M (2013) The effect of topiramate on weight loss in patients with type 2 diabetes. J Res Med Sciences: Official J Isfahan Univ Med Sci 18:297\u2013302","journal-title":"J Res Med Sciences: Official J Isfahan Univ Med Sci"},{"key":"6745_CR48","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.drugalcdep.2016.06.027","volume":"166","author":"KC Morley","year":"2016","unstructured":"Morley KC, Logge W, Pearson S-A, Baillie A, Haber PS (2016) National trends in alcohol pharmacotherapy: findings from an Australian claims database. Drug Alcohol Depend 166:254\u2013257","journal-title":"Drug Alcohol Depend"},{"key":"6745_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s13063-018-2824-z","volume":"19","author":"KC Morley","year":"2018","unstructured":"Morley KC, Kranzler HR, Luquin N et al (2018) Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials 19:443","journal-title":"Trials"},{"key":"6745_CR47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1176\/appi.ajp.20230666","volume":"181","author":"KC Morley","year":"2024","unstructured":"Morley KC, Kranzler HR, Luquin N et al (2024) Topiramate Versus Naltrexone for Alcohol Use Disorder: a genotype-stratified double-blind randomized controlled trial. Am J Psychiatry 181:403\u2013411","journal-title":"Am J Psychiatry"},{"key":"6745_CR49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/adb.12503","volume":"23","author":"LS Morris","year":"2018","unstructured":"Morris LS, Baek K, Tait R et al (2018) Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. Addict Biol 23:425\u2013436","journal-title":"Addict Biol"},{"key":"6745_CR50","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archpsyc.65.4.466","volume":"65","author":"H Myrick","year":"2008","unstructured":"Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K (2008) Effect of Naltrexone and Ondansetron on Alcohol Cue\u2013Induced activation of the ventral striatum in Alcohol-Dependent people. Arch Gen Psychiatry 65:466\u2013475","journal-title":"Arch Gen Psychiatry"},{"key":"6745_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/nyas.12415","volume":"1316","author":"NH Naqvi","year":"2014","unstructured":"Naqvi NH, Gaznick N, Tranel D, Bechara A (2014) The insula: a critical neural substrate for craving and drug seeking under conflict and risk. Ann N Y Acad Sci 1316:53\u201370","journal-title":"Ann N Y Acad Sci"},{"key":"6745_CR52","doi-asserted-by":"crossref","unstructured":"Nieto-Castanon A, Whitfield-Gabrieli S (2021) CONN functional connectivity toolbox (RRID: SCR_009550), Version, vol 21. Hilbert","DOI":"10.56441\/hilbertpress.2161.7292"},{"key":"6745_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/00952990.2014.927881","volume":"41","author":"LA Ray","year":"2015","unstructured":"Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED (2015) Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. Am J Drug Alc Abuse 41:35\u201344","journal-title":"Am J Drug Alc Abuse"},{"key":"6745_CR53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/00952990.2018.1528265","volume":"45","author":"LA Ray","year":"2019","unstructured":"Ray LA, Bujarski S, Grodin E et al (2019) State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alc Abuse 45:124\u2013140","journal-title":"Am J Drug Alc Abuse"},{"key":"6745_CR55","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/acer.14771","volume":"46","author":"JD Robinson","year":"2022","unstructured":"Robinson JD, Cui Y, Karam-Hage M et al (2022) Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder. Alcoholism: Clin Experimental Res 46:384\u2013395","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"6745_CR56","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2337\/dc06-2001","volume":"30","author":"J Rosenstock","year":"2007","unstructured":"Rosenstock J, Hollander P, Gadde KM et al (2007) A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to assess the efficacy and Safety of Topiramate Controlled Release in the treatment of obese type 2 Diabetic patients. Diabetes Care 30:1480\u20131486","journal-title":"Diabetes Care"},{"key":"6745_CR57","doi-asserted-by":"crossref","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010) Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"6745_CR58","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.neuroimage.2012.08.052","volume":"64","author":"TD Satterthwaite","year":"2013","unstructured":"Satterthwaite TD, Elliott MA, Gerraty RT et al (2013) An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. NeuroImage 64:240\u2013256","journal-title":"NeuroImage"},{"key":"6745_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1369-1600.2012.00464.x","volume":"18","author":"JP Schacht","year":"2013","unstructured":"Schacht JP, Anton RF, Myrick H (2013a) Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol 18:121\u2013133","journal-title":"Addict Biol"},{"key":"6745_CR60","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/npp.2012.195","volume":"38","author":"JP Schacht","year":"2013","unstructured":"Schacht JP, Anton RF, Voronin KE et al (2013b) Interacting effects of Naltrexone and OPRM1 and DAT1 variation on the neural response to Alcohol cues. Neuropsychopharmacology 38:414\u2013422","journal-title":"Neuropsychopharmacology"},{"key":"6745_CR61","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/npp.2017.74","volume":"42","author":"JP Schacht","year":"2017","unstructured":"Schacht JP, Randall PK, Latham PK et al (2017) Predictors of Naltrexone Response in a Randomized Trial: reward-related brain activation, OPRM1 genotype, and Smoking Status. Neuropsychopharmacology 42:2640\u20132653","journal-title":"Neuropsychopharmacology"},{"key":"6745_CR62","first-page":"3095","volume":"28","author":"A Schaefer","year":"2018","unstructured":"Schaefer A, Kong R, Gordon EM et al (2018) Local-global parcellation of the Human Cerebral Cortex from intrinsic functional connectivity MRI. Cereb Cortex (New York NY: 1991) 28:3095\u20133114","journal-title":"Cereb Cortex (New York NY: 1991)"},{"key":"6745_CR63","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/syn.10000","volume":"42","author":"WK Schiffer","year":"2001","unstructured":"Schiffer WK, Gerasimov MR, Marsteller DA et al (2001) Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 42:196\u2013198","journal-title":"Synapse"},{"key":"6745_CR64","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1037\/0021-843X.91.3.199","volume":"91","author":"HA Skinner","year":"1982","unstructured":"Skinner HA, Allen BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91:199\u2013209","journal-title":"J Abnorm Psychol"},{"key":"6745_CR65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption: psychosocial and biochemical methods","author":"LC Sobell","year":"1992","unstructured":"Sobell LC, Sobell MB (1992) Timeline Follow-Back. In: Litten RZ, Allen JP (eds) Measuring Alcohol Consumption: psychosocial and biochemical methods. Humana, Totowa, NJ, pp 41\u201372"},{"key":"6745_CR76","doi-asserted-by":"crossref","unstructured":"Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84(11):1353\u20131357","DOI":"10.1111\/j.1360-0443.1989.tb00737.x"},{"key":"6745_CR66","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/archpsyc.60.7.727","volume":"60","author":"SF Tapert","year":"2003","unstructured":"Tapert SF, Cheung EH, Brown GG et al (2003) Neural response to Alcohol Stimuli in adolescents with Alcohol Use Disorder. Arch Gen Psychiatry 60:727\u2013735","journal-title":"Arch Gen Psychiatry"},{"key":"6745_CR67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41398-022-01792-6","volume":"12","author":"S Tolomeo","year":"2022","unstructured":"Tolomeo S, Yu R (2022) Brain network dysfunctions in addiction: a meta-analysis of resting-state functional connectivity. Transl Psychiatry 12:41","journal-title":"Transl Psychiatry"},{"key":"6745_CR68","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/s41386-021-00968-w","volume":"46","author":"RR Wetherill","year":"2021","unstructured":"Wetherill RR, Spilka N, Jagannathan K et al (2021) Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial. Neuropsychopharmacology 46:1414\u20131420","journal-title":"Neuropsychopharmacology"},{"key":"6745_CR69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","volume":"41","author":"HS White","year":"2000","unstructured":"White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH (2000) Topiramate modulates GABA-Evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41:17\u201320","journal-title":"Epilepsia"},{"key":"6745_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/brain.2012.0073","volume":"2","author":"S Whitfield-Gabrieli","year":"2012","unstructured":"Whitfield-Gabrieli S, Nieto-Castanon A (2012) Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect 2:125\u2013141","journal-title":"Brain Connect"},{"key":"6745_CR71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pnpbp.2018.06.011","volume":"91","author":"CE Wilcox","year":"2019","unstructured":"Wilcox CE, Abbott CC, Calhoun VD (2019) Alterations in resting-state functional connectivity in substance use disorders and treatment implications. Prog Neuropsychopharmacol Biol Psychiatry 91:79\u201393","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6745_CR72","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0924-9338(02)00676-4","volume":"17","author":"J Wrase","year":"2002","unstructured":"Wrase J, Gr\u00fcsser SM, Klein S et al (2002) Development of alcohol-associated cues and cue-induced brain activation in alcoholics. Eur Psychiatry 17:287\u2013291","journal-title":"Eur Psychiatry"},{"key":"6745_CR73","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neubiorev.2021.06.031","volume":"128","author":"J Zeng","year":"2021","unstructured":"Zeng J, Yu S, Cao H, Su Y, Dong Z, Yang X (2021) Neurobiological correlates of cue-reactivity in alcohol-use disorders: a voxel-wise meta-analysis of fMRI studies. Neurosci Biobehav Rev 128:294\u2013310","journal-title":"Neurosci Biobehav Rev"},{"key":"6745_CR74","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neuroimage.2019.06.036","volume":"200","author":"R Zhang","year":"2019","unstructured":"Zhang R, Volkow ND (2019) Brain default-mode network dysfunction in addiction. NeuroImage 200:313\u2013331","journal-title":"NeuroImage"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06745-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:03:18Z","timestamp":1751533398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06745-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6745"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06745-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology\u2019s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and a holder of U.S. patent 10,900,082 titled: \u2018Genotype-guided dosing of opioid agonists,\u2019 issued 26 January 2021. Dr Haber has received institutional research support from Camurus, Indivior and Woke pharmaceuticals and teaching honoraria from Camurus.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}